We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

129 hedge funds and large institutions have $685M invested in VanEck Pharmaceutical ETF in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 41 increasing their positions, 43 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

37.15% more ownership

Funds ownership: 78.35% → 115.5% (+37%)

29% more capital invested

Capital invested by funds: $531M → $685M (+$153M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 43

5% less funds holding

Funds holding: 136 → 129 (-7)

25% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 24

92% less call options, than puts

Call options by funds: $3.32M | Put options by funds: $41.4M

Holders
129
Holders Change
-7
Holders Change %
-5.15%
% of All Funds
1.7%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
18
Increased
41
Reduced
43
Closed
24
Calls
$3.32M
Puts
$41.4M
Net Calls
-$38.1M
Net Calls Change
+$24.9M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$139M
2
Morgan Stanley
Morgan Stanley
New York
+$38.7M
3
Wells Fargo
Wells Fargo
California
+$34.9M
4
CI
Clal Insurance
Israel
+$28.2M
5
Jane Street
Jane Street
New York
+$23.4M

Top Sellers

Rank Fund Capital Flow
1
Fisher Asset Management
Fisher Asset Management
Washington
-$110M
2
QC
Quadrature Capital
United Kingdom
-$12.4M
3
Bank of America
Bank of America
North Carolina
-$10.3M
4
UBS Group
UBS Group
Switzerland
-$5.05M
5
Two Sigma Investments
Two Sigma Investments
New York
-$4.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Cetera Investment Advisers
26
Cetera Investment Advisers
Illinois
$3.17M +$120K +1,387 +4%
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
$3.09M -$2.81M -32,433 -48%
TRCT
28
Tower Research Capital (TRC)
New York
$3.05M +$3M +34,614 +346,140%
BCI
29
Brinker Capital Investments
Pennsylvania
$2.95M -$171K -1,977 -6%
Citadel Advisors
30
Citadel Advisors
Florida
$2.75M -$879K -10,135 -24%
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$2.66M +$2.62M +30,254 New
AGC
32
Aspen Grove Capital
Colorado
$2.27M +$13K +150 +0.6%
Raymond James Financial
33
Raymond James Financial
Florida
$1.97M +$205K +2,363 +12%
Osaic Holdings
34
Osaic Holdings
Arizona
$1.95M +$866K +9,992 +82%
Thrivent Financial for Lutherans
35
Thrivent Financial for Lutherans
Minnesota
$1.82M +$1.79M +20,681 New
Qube Research & Technologies (QRT)
36
Qube Research & Technologies (QRT)
United Kingdom
$1.42M +$1.39M +16,074 +13,857%
SPIA
37
Steward Partners Investment Advisory
New York
$1.42M – – –
Fisher Asset Management
38
Fisher Asset Management
Washington
$1.32M -$110M -1,263,699 -99%
Renaissance Technologies
39
Renaissance Technologies
New York
$1.27M +$1.25M +14,400 New
EH
40
Equitable Holdings
New York
$1.25M +$19.6K +226 +2%
Commonwealth Equity Services
41
Commonwealth Equity Services
Massachusetts
$1.17M -$463K -5,339 -29%
Northwestern Mutual Wealth Management
42
Northwestern Mutual Wealth Management
Wisconsin
$1.13M +$481K +5,553 +77%
William Blair & Company
43
William Blair & Company
Illinois
$1.08M +$272K +3,140 +34%
Stifel Financial
44
Stifel Financial
Missouri
$1.01M -$520 -6 -0.1%
Bank of Montreal
45
Bank of Montreal
Ontario, Canada
$1M -$363K -4,190 -27%
OC
46
Oppenheimer & Co
New York
$977K +$19.8K +228 +2%
CH
47
Canton Hathaway
Rhode Island
$880K – – –
HI
48
Hudock Inc
Pennsylvania
$811K +$799K +9,217 New
AWM
49
Axxcess Wealth Management
California
$802K +$36.1K +416 +5%
FFL
50
Financial Freedom LLC
Ohio
$792K +$1.3K +15 +0.2%
1
2
3 4 5

PPH Hedge Fund Activity: Q2 2025 in Review

129 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2025, worth a combined $685M — up 29% from $531M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of PPH and 18 opened new positions — a net loss of 6 holders — while 43 trimmed existing stakes and 41 added.

The largest buyer was Goldman Sachs, adding an estimated $139M. The largest seller was Fisher Asset Management, cutting an estimated $110M.

  • 129 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2025, down from 136 in Q1 2025.
  • Funds reported $685M of VanEck Pharmaceutical ETF stock for Q2 2025, up 29% quarter-over-quarter.
  • 18 funds opened new VanEck Pharmaceutical ETF positions in Q2 2025 and 24 closed out, a net change of -6 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q2 2025 was Goldman Sachs, an estimated $139M added.
  • The largest VanEck Pharmaceutical ETF seller in Q2 2025 was Fisher Asset Management, an estimated $110M sold.

Based on aggregated 13F filings for Q2 2025.